Tonetti, Debra A., Ph.D.
CURRICULUM VITAE
Debra A. Tonetti, Ph.D.
Department of Biopharmaceutical Sciences
College of Pharmacy
University of Illinois at Chicago
(312) 413-1169 (Office)
(312) 996-1698 (Fax)
email: dtonetti@uic.edu
PROFESSIONAL EXPERIENCE
2007-present
Associate Professor of Pharmacology, with tenure
Department of Biopharmaceutical Sciences
Cancer Center Member
University of Illinois at Chicago
2001-2007
Assistant Professor of Pharmacology
Department of Biopharmaceutical Sciences
Cancer Center Member
University of Illinois at Chicago
2002-present
Affiliate Faculty, Center for Pharmaceutical Biotechnology
University of Illinois at Chicago
2003-present
Member of the Graduate College
University of Illinois at Chicago
1996-2001
Research Assistant Professor
Robert H. Lurie Comprehensive Cancer Center
Northwestern University Medical School
1994-1996
Senior Research Associate
Laboratory of Dr. V. Craig Jordan
Robert H. Lurie Cancer Center
Northwestern University Medical School
1989-1994
Enrico Fermi Postdoctoral Fellow
Laboratory of Dr. Eli Huberman
Center for Mechanistic Biology and Biotechnology
Argonne National Laboratory
1
Tonetti, Debra A., Ph.D.
EDUCATION
1984-1990
Doctor of Philosophy
Laboratory of Dr. Robert V. Miller
Department of Molecular and Cellular Biochemistry
Loyola University of Chicago
1983-1985
Master of Science
Laboratory of Dr. Howard M. Laten
Department of Biology
Loyola University of Chicago
1977-1980
Bachelor of Science
Major: Biology; Minor: Chemistry
Northern Illinois University
FUNDING
Active
2015-2018
NIH RO1CA188017-01
Project title: Partial Agonists at Estrogen Receptor α for Breast Cancer
Therapy
Total Costs: $ 1,698,578.00
Funding Period: 05/01/15-04/30/18
Percent effort and salary: 10%
PI: Thatcher
Role: Co-Investigator
2015-2016
University of Illinois Foundation Philanthropic Gift
Project title: Lung Cancer Patient-Derived Xenografts
Total Costs: $100,000
Funding Period: 7/15/15-7/14/16
Role: PI
2015-2020
NIH/NCIR01 CA200669-01 (Frasor)
Project title: Estrogen Receptor and NFkB Crosstalk in Breast Cancer
Costs: $294,378
Funding period: 9/01/15-8/31/20
Role: Co-I
Pending
2016-2017:
DOD LCRP LC150606
Project title: The Role of PKCalpha in Drug-Resistant Lung Cancer
2
Tonetti, Debra A., Ph.D.
Total Costs: $154,951
Funding Period: 04/01/16-03/31/17
Role: PI
Past
2010-2015
NIH Supported Centers for Population Health and Health Disparities
Project title: DNA Methylation and Differential Breast Cancer
Aggressiveness by Race/Ethnicity (Project 3)
Total Costs: $9,999,770
Funding Period: 4/01/10-3/31/15
PI: R. Warnecke
Percent effort and salary: 5%
Role: Co-Investigator
2014
UIC Cancer Center Pilot Grant (PI)
Project title: Establishment of a relevant breast cancer pre-clinical model:
Patient-Derived Xenografts
Total Costs: $50,000
Funding Period: 03/01/14-02/28/15
Percent effort and salary: 5% effort and 0% salary
Role: PI
2013
Proof of Concept
Project title: SEMs for the Treatment of Tamoxifen-Resistant Breast
Cancer
Total Costs: $50,000
Funding Period: 01/07/13-06/30/15
Percent Effort: 5%
Role: Co-PIs Debra Tonetti, Greg Thatcher. Lucy Chen
2013
CCTS Pilot Grant CCTS0413-04
Project Title: Mechanism of action of TTC-352 for the treatment of
endocrine-resistant breast cancer
Funding period: 05/01/13-04/30/14Total Costs: $30,000 Percent Effort: 10%
Co-PI: Gregory Thatcher
Role: PI
2010-2013
Avon Foundation
Project title: Breast Cancer Risk Prediction Based on a Parity-Associated
Gene Signature
Total Costs: $300,000
Funding Period: 7/1/10-6/30/13 (no cost extension)
Percent effort and salary: 10%
PI: D.A. Tonetti
3
Tonetti, Debra A., Ph.D.
2007-2013
NIH/NCI R01 CA122914-05
Project title: PKC Alpha as a Marker for Logical Therapeutic Approaches
to Breast Cancer
Total Costs: $2,242,342
Funding Period: 06/01/07-04/30/13 (2013 no cost extension)
Percent Effort and Salary: 20%
Role: PI
2010-2012
Chicago Biomedical Consortium Catalyst Award
Project Title: Application of 3D Cell Culture and Signaling Arrays in a
Breast Cancer Model
Funding Period: 2/01/10-1/31/12
Total Costs: $100,000
Percent Effort: 5%
Co-PIs: Debra Tonetti and Lonnie Shea
Role: Co-PI
2006-2010
Avon Foundation
Project title: Molecular Evidence of the Role of Lobular Involution in
Pregnancy-Associated Breast Cancer
Total Costs: $650,000
Funding Period: 08/31/06-6/30/10
Percent Effort and Salary: 10%
Role: PI
2007-2012
NIH, NICHHD, 1K12HD055892-01
Building Interdisciplinary Research Careers in Women’s Health
Total Costs: $2.5M
Funding Period: 9/1/2007 – 8/31/2012
PI: Stacie Geller
Role: Mentor
2008-2009
IDPH, Penny Severns Breast, Cervical and Ovarian Cancer Research
Fund
Project Title: Clinical Value of Aromatase Inhibitor Therapy in PKCα
Overexpressing Breast Cancer
Total Costs: $60,000
Funding Period: 07/01/08-06/30/09
% Effort and Salary: 10%
Role: PI
2004-2009
NIH, NIGMS T32 BM070388
Pharmacological Sciences Training Program
Total Costs: $990,336
4
Tonetti, Debra A., Ph.D.
Funding Period: 07/01/05-06/30/09
PI: AB Malik
Role: Preceptor
2005-2007
Susan G. Komen Breast Cancer Foundation
Total Costs: $250,000
Funding Period: 05/01/05-04/30/07
Project title: Mechanism of Protein Kinase C Alpha-Mediated Tamoxifen
Resistant Breast Cancer
% Effort and Salary: 10%
Role: PI
2004-2006
NIH/NCI P50 CA106743
Pilot Study
UIC Centers for Population Health and Health Disparities
Total Costs: $80,000
Funding Period: 08/15/04-08/14/06
Project Title: The role of PKCα and ERβ in aggressive breast cancer in
African-American breast cancer patients
Role:PI
2001-2005
NCCAM RO1 CA96517 (Botanical/Drug Interactions)
Andreas Constantinou (PI)
Award: $1,320,666
Funding Period: 08/01/01-07/31/04 (8/01/04-7/31/05 no cost) Project
title: Mechanism(s) of antitumor action of tamoxifen and soy
% Effort and Salary: 20%
Role: Co-Investigator
2002-2005
NIH R21 CA97045
(Exploratory Studies in Cancer Detection, Prognosis and Prediction)
Total Costs: $336,116
Funding Period: 9/01/02-8/31/05 (9/1/04-8/31/05 no cost)
Project Title: PKCoverexpression as a marker in tamoxifen-resistant
breast cancer
% Effort and Salary: 10%
Role: PI
2003-2004
Vahlteich Research Award, College of Pharmacy, UIC
Total Costs: $27,000
Funding Period: 07/01/03-06/30/04
Project title: “Mechanism of Estradiol-Mediated Regression of Protein
Kinase C Alpha-Overexpressing Breast Tumors”
Role: PI
5
Tonetti, Debra A., Ph.D.
2002-2003
University of Illinois at Chicago Campus Research Board
Total Costs: $15,000
Funding Period: 07/01/02-6/30/03
Project title: “PKC-Mediated Antitumor Effect of E2 in TAM-Resistant
Breast Cancer”
Role: PI
2000-2001
Avon Breast Cancer Crusade, Avon Products Foundation
03/07/00-03/06/01
Total Costs: $50,000
Title: “Protein Kinase C as a Mechanism of Antiestrogen Resistance”
Role: PI of Project
Overall PI: Monica Morrow, M.D.
1998-2001
NIH NCI R01 CA79847
12/08/98-11/3/01
Total Costs: $433,590
Title: “The Role of Protein Kinase C in Tamoxifen-Stimulated Tumor
Growth”
% Effort and salary: 65%
Role: PI
1997-1998
American Cancer Society Illinois Division
Total Costs: $34,909
Title: “Tamoxifen-Resistant Breast Cancer and PKC Isozyme Expression”
% Effort and salary: 80%
Role: PI
CLINICAL TRIAL
Phase II Study of Estradiol Therapy in Metastatic Breast Cancer and Protein Kinase C as a
Potential Biomarker (Lucy Chen, M.D., PI)
Role: Co-I
PATENTS
Application: Compositions and Methods for Treating Estrogen-Related Medical Disorders
13848485.8 – 1453 PCT/US2013066699
HONORS
1984-1985
1988-1989
1989
2003-2004
Basic Science Fellowship, Loyola University of Chicago
University Dissertation Fellowship, Loyola University of Chicago
Enrico Fermi Scholar, Argonne National Laboratory
Vahlteich Scholar, College of Pharmacy, UIC
PROFESSIONAL ASSOCIATIONS
6
Tonetti, Debra A., Ph.D.
Member, American Association for Cancer Research (AACR)
Member, American Society for Pharmacology and Experimental Therapeutics (ASPET)
Member, Women in Cancer Research
SERVICE
Editorial Board Member, Breast Cancer – Targets and Therapy (2010-present)
Editorial Board Member, International Journal of Breast Cancer (2009-present)
Guest Editor, International Journal of Breast Cancer, Special Issue on New Concepts in
Resistance to Breast Cancer Treatment
Review Editor, Frontiers in Cancer Genetics (2011-present)
Councilor, Great Lake Chapter of the American Society for Pharmacology and
Experimental Therapeutics (ASPET) (2009-2010)
Manuscript Reviewer (Ad Hoc):
Biomarkers
BMC Cancer
British Journal of Cancer
Breast Cancer Research
Breast Cancer Research and Treatment
Cancer Research
Clinical Cancer Research
Cancer Chemotherapy and Pharmacology
Cancer Letters
Combinatorial Chemistry & High Throughput Screening
Carcinogenesis
Endocrinology
Endocrine-Related Cancer
Hormones and Cancer
Molecular Carcinogenesis
Molecular Cancer Research
Molecular Cancer Therapeutics
Nutrition and Cancer
Oncogene
Oncology Research
PLOS One
Steroid Biochemistry & Molecular Biology
Study Sections:
Scientist Reviewer, END-2 panel Department of Defense Breast Cancer Study Section 19982000, 2004, 2009-2010.
Scientist Reviewer, MBG panel Department of Defense Breast Cancer Study Section, 2005 and
2007-2008
Member, American Cancer Society Research Advisory Committee, Illinois Division 2000-2004.
NIH NCI Ad Hoc Committee Member (2003), Program Project Site Visit
Grant Reviewer, Sheffield Hospital Charitable Trust, University of Sheffield, UK, Dec. 2003.
7
Tonetti, Debra A., Ph.D.
NIH NIA Ad Hoc Committee Member (2004), Program Project Site Visit
Peer Review Panel Member, Penny Severns Breast, Cervical and Ovarian Cancer Research
Fund, Illinois Department of Public Health, Office of Women’s Health 2006-2007.
Scientist Reviewer, OCRP Concepts, Department of Defense, Online Reviewer, 2007
Scientist Reviewer, IPA-2 panel Department of Defense Breast Cancer Study Section, 2009
Ad-Hoc Member Scientific Advisory Board, Avon Foundation Grant Review, 2009-2010, 2012.
NIH/CSR Special Emphasis Panel ZRG1 BDA-A 58, Mail Reviewer, July 2009
Scientist Reviewer, BCRP Concepts CET-3 Panel, DOD, Online Reviewer, 2010
Scientist Reviewer, BCRP CET2 Panel, Department of Defense, 2012, 2013
Scientist Reviewer, BCRP CET5 Panel, Department of Defense, 2015
Scientific Review Board, Chicago Biomedical Consortium, 2012-present.
External Advisory Panel for Breast Cancer SPORE, Northwestern University, 2012
Grant Reviewer, University of Svöde, 2012
Grant Reviewer, University of Pennsylvania State University Formula Grant 2013
Grant Reviewer, Florida Department of Health and ORAU Grant Review 2015
University Review
2007 Graduate and Professional Student Research Forum Judge
Internal Research Grants Competition at the University of Illinois College of Medicine at
Rockford.
2010-2015 Chancellor's Supplemental Graduate Research Fellowship Program Reviewer
2011, 2014, 2015 College of Pharmacy Research Days, Poster Judge
2014, 2015 Cancer Center Research Day, Poster Judge
TRAINING EXPERIENCE
Member of Dissertation Committee for the following students:
Joanna Burdette, Dept. of Pharmacognosy, UIC. Ph.D., 2003
Nicole Darack, Molecular & Cellular Biochemistry, Loyola University, Ph.D., 2004
Rachel Ee, Biopharmaceutical Sciences, Ph.D., 2004
Hong Liu, Dept of Medicinal Chemistry, UIC. Ph.D., 2005 Jovita
Tauro, Biopharmaceutical Sciences, UIC, Ph.D., 2005 Joaquina
Mascarenas, Biopharmaceutical Sciences, UIC 2006
Adina Stanculescu, Center for Pharmaceutical Biotechnology, UIC, Ph.D. 2006 Lei
Tang, Biopharmaceutical Sciences, UIC, Ph.D. 2006
Cassia Overk, Dept of Medicinal Chemistry, UIC, Ph.D. 2007
Jieun Yun, Biopharmaceutical Sciences, Ph.D. 2007
Marianna Halasi, Biochemistry and Molecular Genetics, Ph.D.2012 Yalda
Afshar, Physiology and Biophysics, MD pending/Ph.D. 2010 Deepali
Vartak, Biopharmaceutical Sciences, UIC, Ph.D. 2009
Zhican Wang, Dept of Medicinal Chemistry, UIC, Ph.D. 2009 Gwendolyn
D’Souza, Biopharmaceutical Sciences, UIC, Ph.D. 2010
Ramy Essam Abdelhamid, Dept of Medicinal Chemistry, UIC, Ph.D. pending
Teshome Gherezghiher, Dept. of Medicinal Chemistry, UIC, Ph.D. 2011
8
Tonetti, Debra A., Ph.D.
Indraneel Kundu, Dept. of Medicinal Chemistry, UIC, Ph.D. pending
Songpil Cho, Biopharmaceutical Sciences, UIC, Ph.D. 2009
Kuanwei Peng, Dept. of Medicinal Chemistry, UIC, Ph.D. 2009
Zhican Chen, Dept of Medicinal Chemistry, UIC, Ph.D. 2009
Bolan Yu, Dept of Medicinal Chemistry, UIC, Ph.D. 2010
Cheng-Fen (Terri) Chen, Biopharmaceutical Sciences, UIC, Ph.D. 2011 TsuiTing Ho, Biopharmaceutical Sciences, UIC, Ph.D. 2012
Sumit Sahni, Dept. of Medicinal Chemistry, UIC, Ph.D. 2011 Kinnari
Mehta, Loyola University, Ph.D. 2013
Bradley Michelson, Dept. of Medicinal Chemistry, UIC, Ph.D. 2013
Maoyu Peng, Dept. of Molecular Genetics, UIC, Ph.D. 2013
Atieh Hajirahimkhan, Dept of Pharmacognosy, UIC, Ph.D. pending
Brian Shy, Dept of Molecular Genetics, UIC Ph.D. pending
Hitisha Patel, Dept. of Medicinal Chemistry, UIC, Ph.D. pending
Madhubhani Hemachandra, Dept. of Medicinal Chemistry, UIC, Ph.D. pending
Yang Yang, Biopharmaceutical Sciences, UIC, Ph.D. 2013
Yu Zhang, Biopharmaceutical Sciences, UIC, Ph.D. 2015
Rui Xiong, Dept. of Medicinal Chemistry, UIC, Ph.D., pending
Current Ph.D. Graduate Student:
Thao Nguyen Pham, September 2011-present
Past M.S. Graduate Student:
Huifang Han, M.S., July 2008-2011
Past Ph.D. Graduate Students:
Yiyun Zhang, Ph.D., August 2008
Current position: Postdoctoral Fellow, Harvard Medical School
Bethany White, Ph.D., July 2012
Current position: Postdoctoral Fellow, Northwestern University School
Mary Ellen Molloy, Ph.D., January 2014
Current position: Postdoctoral Fellow, Harvard Medical School
Pharm.D. Students:
Meghan Hayes, July 2007-2009 Rutu
Joshi, June 2009-June 2010 Sybille
Lupee, July 2010-2012
Sabrina Sanchez, Jan 2013-August 2013
Jenny Le, May 2013-September 2013
Undergraduate Volunteers:
Ahmed Mahafzah, pre-pharmacy, Aug. 2004-2005
Mary Ellen Molloy, pre-pharmacy, July 2007-May 2008
9
Tonetti, Debra A., Ph.D.
Past Postdoctoral Fellows:
Szilard Asztalos, Ph.D., 2006-2012
Mahducchanda Kundu, Ph.D., 2008-2011
Mohamed Nasr, Ph.D. 2004-2005
Xin Lin, Ph.D., 2003- 2004
Yasmin Ahmed, Ph.D., 2000-2001
Past Masters Students:
Northwestern University Center for Biotechnology Graduate Program
Anna Berdine, M.S., 1997 graduate
Wendy Grdina, M.S., 1998 graduate
Heather Schurz, M.S., 1998 graduate
David Fournier, M.S., 1999 graduate
Robyn Pike, M.S., 2001 graduate
Jessica Manela, M.S., 2001 graduate
Summer Students:
Northwestern University Medical Students
Jason Bradfield, summer, 1999
Sharon Shen, summer, 2000
Connie Rhee, summer 2001
Northwestern University Pre-med undergraduate student
Jonathan Berger, summers 1997 and 1999
Whitney Young Magnet High School Student, American Cancer Society Summer Research
Program:
Margaret Sharp, Summer 2003
Urban Pipeline Program
Under-represented Minority High School Pathways to Pharmacy/Science Program
Summer 2010 and 2011
Biopharmaceutical Sciences, Pharmaceutical Biotechnology Center, MD/Ph.D Rotation
Students
Aarti Lalla (BPS,2002)
Qi Shen (PBC, 2003)
Denise Holzle (PBC, 2004)
Sok Bee Lee (BPS, 2005)
Su-Young Choi (PBC, 2005)
Zhican Chen (PBC, 2005)
Jin Wha Song (PBC, 2006)
10
Tonetti, Debra A., Ph.D.
Lila Gollogly (MSTP, MD/Ph.D. 2006)
Tsui-Ting Ho (BPS, 2006)
Huifang Han (BPS, 2008)
April Szafran (MD, 2009)
Ying Gao (BPS, 2010)
Lamiaa El-Shennawy (BPS, 2011)
Thao Pham (BPS, 2011)
Amanda Mennie (MSTP, MD/Ph.D. 2012)
Joelle Sachs, (BPS, 2012)
Dulari Jayawardena (BPS, 2014)
Ashita Nair (BPS, 2015)
Yukuang Gau (BPS, 2016)
2004-2006, 2014 Coordinator of Campus-Wide Breast Cancer Journal Club
2008-2010 NIH K12 Award
Mentor, Building Interdisciplinary Research Careers in Women’s Health (BIRCWH)
Hyungyoung Jeong, Pharm.D.,Ph.D., Assistant Professor, Departments of Pharmacy Practice and
Biopharmaceutical Sciences, UIC College of Pharmacy
TEACHING ACTIVITES
Graduate
Spring, 2002
Spring,
2003-present
Spring, 2002-2005
2003-2005
2009-2010
2001-present
Spring, 2004
Fall, 2006-2007
Spring, 2005
Introduction to Pharmaceutical Research (PMPC 495)
2 hours of lectures
Biopharmaceutical Sciences II (BPS 502), Course Co-Coordinator
17 hours of lectures
Biological Evaluation of Natural Products (PMPG 480)
1 hour lecture
Departmental Seminar (BPS 595), Course Co- Coordinator
Research in Biopharmaceutical Sciences (BPS 593)
Pharmacogenomics (BPS 555)
1 hours lecture, Genes and Genetics
Advanced Cancer Epidemiology, School of Public Health
2 hour lecture, Breast Cancer Therapies
11
Tonetti, Debra A., Ph.D.
Spring, 2005
Tumor Cell Biology, Northwestern University
1 hour lecture, Breast Cancer Therapies and Mechanisms of Action
Fall, 2006
Neuroendocrinology
2 hour lecture, ER and SERMs
2008-present
BPS 553, Cancer Biology and Therapeutics
Course originator and Co-Coordinator
6 hours lecture
Fall 2010
PATH 510, Pathobiology of Cancer
1.5 hour lecture
Professional
Fall, 2002
Spring, 2004
BPS 380, Undergraduate Research in Biopharmaceutical Sciences
Asha Sztark, P2 student
Erika Meredith, P1 student
Fall 2001-2006
Clinical Pharmacology (BPS 470)
1 hour lecture, SERMs
Fall 2003-present
Phar 321, Drug Delivery Systems I: Pharmaceutical Dosage Forms
and Drug Delivery Systems
2 hours lecture, GI Physiology & Drug Absorption; Drug Metabolism &
Pharmacogenomics
Spring 2006-2007
Spring 2006-2007
2010
Phar 404, Principles of Drug Action and Therapeutics IV
1 hour lecture, Pharmacology of Female Sex Hormones
PMPR 355, Research Seminar
1 hour lecture
Spring 2008-present Phar 404, Principles of Drug Action and Therapeutics IV
Course Coordinator
1 hour lecture, Pharmacology of Female Sex Hormones
COMMITTEES
University Level
Spring, 2005
Fall 2009-2012
Senator, Senate of the University of Illinois at Chicago
12
Tonetti, Debra A., Ph.D.
2009/2010
2010/2011
Member, Senate Committee on Student Affairs
Chair, Senate Committee on Student Affairs
Fall 2007
Member, Membership Subcommittee of the Cancer Center Transition
Advisory Membership Committee
Spring/Fall 2008
Member, Search Committee for Associate Director of Cancer Control,
Population Science and Education, UIC Cancer Center
2010-present
Admissions Committee, Medical Scientist Training Program
2015-
Member, Cancer Center Protocol Review Committee
College Level
2002
2002-2003
Member, College of Pharmacy Strategic Planning Committee
Member, Student/Faculty Relations Committee
2003-2004
Member, Research Committee
2004-2010
Member, Executive Committee, Pharmacological Sciences Training
Program
2005-2010
Member, Advisory Committee, UIC/NIH Center for Botanical Dietary
Supplements Research
2006
Member, Salary Bonus/Award Committee
2006-2007
Member, ACPE Self-Study Subcommittee
2006-2007
2007
Member, Student Disciplinary Committee
Chair, Vahlteich Award Committee
2007-present
Member, COP Research Advisory Committee
2008-2009
Member, Academic Standing Committee
2009-present
COP Representative to Research Resources Center Executive Advisory
Panel
2010, 2015
Vahlteich Award Committee
2009-present
COP Executive Committee
2012/2014
Member, BPS Forensics Faculty Search Committee
13
Tonetti, Debra A., Ph.D.
2015
Co-Chair, COP Promotion and Tenure Committee
Departmental
2002-present
Member, Student Oversight and Exam Committee
2002-2006
Chair, Department Brochure and Website Committee
2002-2005
Chair, Graduate Program Brochure Committee
2003-present
Member, Graduate Committee
2003-2005
2006-2008
2009-2012
2013-present
Member, Department Advisory Committee
2005-2010
2007
Member, BPS Faculty Search Committee
Member, CBP and BPS Joint Faculty Search Committee
2008-2010
Chair, Seminar and Journal Club Committee
2008-2009
Member, Bi-Laws Committee
2008-2009
Member, Curriculum Committee
2008-2009
Member, Publications Committee
2012
Member, Forensic Science Faculty Search Committee
2014-2016
Member, BPS Faculty Search Committee
INVITED LECTURES
May 25-28, 1997
Antiestrogen stimulated human endometrial cancer growth; laboratory and
clinical considerations. The 13th International Symposium of the
Journal of Steroid Biochemistry & Molecular Biology. Monaco.
January 25, 1999 The Role of Protein Kinase C Alpha Overexpression in TamoxifenResistant Breast Cancer. Department of Molecular and Cellular
Biochemistry, Loyola University Medical Center, Maywood,
IL.
April 7, 1999
The Role of Protein Kinase C Alpha Overexpression in
14
Tonetti, Debra A., Ph.D.
Tamoxifen- Resistant Breast Cancer. Department of Urology,
Northwestern University Medical School, Chicago, IL.
April 6, 2001
Investigation of the PKC Signal Transduction Pathway as it Relates to
Tamoxifen-Resistant Breast Cancer. Department of Pharmaceutics and
Pharmacodynamics, College of Pharmacy, University of Illinois at
Chicago.
October 17, 2002
The Role of the PKC Signaling Pathway in Tamoxifen-Resistant Breast
Cancer. Center for Pharmaceutical Biotechnology, College of
Pharmacy, University of Illinois at Chicago.
April 28, 2003
PKCOverexpression May Predict Tamoxifen Treatment Failure. RushUIC-Stroger Joint Breast Cancer Conference, University of Illinois at
Chicago.
March 10, 2004
PKCα Over-Expression as a Marker of Tamoxifen-Resistant Breast Cancer.
Frontiers of GI Research Seminar, Section of Digestive Diseases,
Department of Medicine, University of Illinois at Chicago.
May 24, 2004
Hormonal, Biological and Chemotherapeutic Approach to Breast Cancer
Treatment. Midwest Association for Toxicology and Therapeutic Drug
Monitoring, Arlington Heights, IL.
November 8, 2004
PKC Alpha May Be a Predictive Marker in Tamoxifen Resistant Breast
Cancer: Implications for Therapy. Visiting Professor Lecture, Rush
Medical College, Department of Pathology, Chicago, IL.
April 11, 2005
PKCα Overexpression in Breast Cancer as a Predictor for Tamoxifen and
Aromatase Inhibitor Treatment Failure: Opportunities for Alternative
Therapeutic Strategies. Cardinal Bernardin Cancer Center, Loyola
University Medical Center, Maywood, IL.
July 22, 2005
PKCα Overexpression in Breast Cancer as a Predictor for Tamoxifen and
Aromatase Inhibitor Treatment Failure: Opportunities for Alternative
Therapeutic Strategies. Elkin Cancer Biology Seminar Series, Emory
Univ. School of Medicine, Winship Cancer Institute, Atlanta, GA.
April 28, 2006
Signal Transduction Mechanisms Mediated by PKCα Overexpression in
Human Breast Cancer Models. Physiology & Biophysics Department,
College of Medicine, University of Illinois at Chicago.
November 9, 2006
Molecular Evidence for the Role of Lobular Involution in PregnancyAssociated Breast Cancer. Avon Foundation Prevention Research
Initiative Symposium. New York, N.Y.
15
Tonetti, Debra A., Ph.D.
October 11, 2006
Prognostic Factors in Breast Cancer: Preclinical Models of Breast Cancer
with Potential Translation to the Clinic. Biopharmaceutical Sciences
Seminar Series, University of Illinois at Chicago.
March 14, 2007
Signal Transduction Mechanisms Mediated by PKCα Overexpression in
Breast Cancer. Department of Biology, Loyola University Chicago,
Chicago, Illinois.
October 8, 2007
Tamoxifen and Soy Effects in Tamoxifen-Resistant Tumors in Mice.
Molecular Targets for Cancer Prevention, Diagnosis and Treatment, an
International Conference. Lemesos, Cyprus.
November 12, 2007
Molecular Evidence for the Role of Lobular Involution in PregnancyAssociated Breast Cancer. Avon Foundation Prevention Research
Initiative Symposium. Houston, TX.
February 20, 2008
The Role of Lobular Involution in Pregnancy-Associated Breast Cancer.
Breast Cancer Program, Robert H. Lurie Comprehensive Cancer
Center, Northwestern University, Chicago.
February 13, 2009
Molecular Evidence for the Role of Lobular Involution in PregnancyAssociated Breast Cancer. Avon Foundation. Prevention: Research and
Strategies for the 21st Century. Miami, FL.
March 25, 2009
A Clinically Relevant Tamoxifen-Resistant Breast Cancer Model Sensitive
to Estradiol-Induced Tumor Regression. Department of Biochemistry
and Molecular Genetics, College of Medicine, University of Illinois at
Chicago.
November 20, 2009
Gene Expression in the Human Breast After Pregnancy: Evidence of
Protection or Increased Risk of Breast Cancer? Cancer Center Research
Seminar, Rush Medical College, Chicago, IL.
January 14, 2010
Gene Expression in the Human Breast After Pregnancy: Evidence of
Protection or Increased Risk of Breast Cancer?
Carcinogenesis/Chemoprevention Program,Cancer Center, UIC,
Chicago, IL.
October 15, 2010
Gene Expression in the Human Breast After Pregnancy: Evidence of
Protection or Increased Risk of Breast Cancer? Department of
Pharmacology, Midwestern University, Downers Grove, IL.
Prognostic Factors in Breast Cancer: Preclinical Models with Potential
Translation to the Clinic. Medical Scientist Training Program Lunch
Seminar Series, UIC, Chicago, IL.
November 3, 2010
16
Tonetti, Debra A., Ph.D.
March 2, 2011
Breast Cancer Risk Prediction Based on a Parity-Associated Gene
Signature. Breast Cancer Prevention and Treatment Research Forum,
Avon Foundation for Women, Apella at Alexandria Center for Life
Science, New York, NY.
March 25, 2011
A Clinically Relevant Tamoxifen-Resistant Breast Cancer Model: Potential
Therapeutic Opportunities. Elkin Cancer Biology Seminar Series,
Emory Univ. School of Medicine, Winship Cancer Institute, Atlanta,
GA.
April 22, 2011
Changes in Cellular Signaling Pathways Measured by High Throughput
Screening. CBC Science Day, Prentice Women’s Hospital Conference
Center, Chicago, IL.
June 8, 2011
PKCα is a Breast Cancer Biomarker. 17th International Charles
Heidelberger Symposium on Cancer Research. The Fourth Military
Medical University In Xi’an, The People’s Republic of China.
August 16, 2011
PKCα: A Potential Breast Cancer Biomarker. Cancer Cell Signaling
Program, Cancer Center, UIC, Chicago, IL.
February 14, 2013
Efficacy of Selective Estrogen Mimics for the Treatment of
PKCα Expressing Breast Cancer. Cancer Chemoprevention Program,
Cancer Center, UIC, Chicago, IL
November 13, 2014
PKCin Endocrine Resistant Breast Cancer: PDX Update. Breast Cancer
Symposium, UI Cancer Center, Chicago, IL.
November 20, 2014
Predictive Value of PKCExpression in Breast Cancer. Department of
Pathology, COM, UIC.
October 20, 2015
Establishment of a Relevant Breast Cancer Preclinical Model: PatientDerived Xenografts. UIC Cancer Center Research Day, Pilot Project
Presentation.
March 14, 2016
Selective Estrogen Mimics for the Treatment of Tamoxifen-Resistant Breast
Cancer using PKCas a Predictive Biomarker. Rockford Colloquium.
PEER-REVIEWED PUBLICATIONS
1. Druse, M. J., D. A. Tonetti and D. M. Smith, Jr. 1982. Effects of maternal nutritional
stress on synaptic plasma membrane proteins and glycoproteins in offspring. Exp. Neurol.
78:99-111.
17
Tonetti, Debra A., Ph.D.
2. Druse, M. J., G. M. Kelly, D. A. Tonetti, and B. G. Oden. 1986. Maternal ethanol
consumption. Binding of L-glutamate to synaptic membranes from whole brain, cortices, and
cerebella from offspring. Exp. Neurol. 91:219-228.
3. Tonetti, D. A., M. Horio, F. Collart, and E. Huberman. 1992. Protein kinase C gene
expression is associated with susceptibility of human promyelocytic leukemia cells to
phorbol ester induced-differentiation. Cell Growth & Differ. 3:739-745.
4. Tonetti, D. A., C. Henning-Chubb, D.T. Yamanishi, and E. Huberman. 1994. Protein
kinase C is required for macrophage differentiation of human HL-60 leukemia cells. J. Biol.
Chem. 269:23230-23235.
5. Tonetti, D.A., O'Regan, R., Tanjore, S., England, G. and Jordan, V.C. 1998. Antiestrogen
stimulated human endometrial cancer growth; laboratory and clinical considerations. J. Ster.
Biochem. Mol. Biol.65: 181-189.
6. Levenson, A.S., Tonetti, D.A. and Jordan, V.C. 1998. The estrogen-like effect of 4hydroxytamoxifen (4-OHT) on induction of transforming growth factor alpha (TGF)
mRNA in MDA-MB-231 breast cancer cells stably expressing the estrogen receptor (ER). Br.
J. Cancer 77:11 1812-1819.
7. Schafer, J.I.M, Liu, H., Tonetti, D.A. and Jordan, V.C. 1999. The interaction of raloxifene and
the active metabolite of the antiestrogen EM-800 (SC 5705) with the human estrogen
receptor. Cancer Res.59: 4308-4313.
8. Tonetti, D.A., Chisamore, M., Grdina, W., Schurz, H. and Jordan, V.C. 2000. Stable
Transfection of Protein Kinase C Alpha cDNA in Hormone-Dependent Breast Cancer Cell
Lines. Br. J. Cancer 83(6):782-791.
9. Fournier, D.B., Chisamore, M., Lurain, J., Rademaker, A., Jordan, V.C. and Tonetti,
D.A. 2001. Protein Kinase C Alpha Expression is Inversely Related to ER Status in
Endometrial Carcinoma: Possible Role in AP-1 Mediated Proliferation of ER Negative
Endometrial Cancer. Gyne Oncol., 81:366-372.
10. Chisamore,M.J., Bentrem, D.B., Ahmed, Y., Jordan, V.C. and Tonetti, D.A. 2001. Novel
antitumor effect of estradiol in athymic mice injected with a T47D breast cancer cell line
overexpressing protein kinase C alpha. Clin. Cancer Res., 7: 3156-3165.
11. Tonetti, D.A., M. Morrow, N. Kidwai, A. Gupta, S. Badve. 2003. Elevated Protein Kinase
C Alpha Expression May Be Predictive of Tamoxifen Treatment Failure. British J. Cancer,
88: 1400-1402.
12. Liu, X., Pisha, E., Tonetti, D.A., Yao, D., Li, Y., Yao, J., Burdette, J.E. and Bolton, J.L.
2003. Antiestrogenic and DNA damaging effects induced by tamoxifen and toremifene
metabolites. Chem. Res. Toxicol, 16: 832-837.
18
Tonetti, Debra A., Ph.D.
13. Tonetti, D.A., Pike, R., Deleon, M., Zhao, H., Pappas, S.G., Bentrem, D., Chen, B.,
Constantinou, A. and Jordan, V.C. 2003. Stable transfection of an estrogen receptor beta
cDNA into MDA-MB-231 breast cancer cells. J. Steroid Biochem. Mol. Biol. 87: 47-55.
14. Ee, P.L.R., Kamalakaran, S., Tonetti, D., He, X., Ross, D.D., and Beck, W.T. 2004.
Identification of a novel estrogen response element in the breast cancer resistance protein
gene. Clin. Cancer Res., 64: 1247-1251.
15. Peng, X., Mehta, R.G., Tonetti, D.A, and Christov, K. 2005. Identification of novel
RARβ2 transcript variants with short 5'-UTRs in normal and cancerous breast epithelial
cells. Oncogene, 24(7):1296-301.
16. Constantinou, A.I., White, B.E.P, Tonetti, D., Y. Wang, Liang, W., Li, W., van Breemen,
R.B. 2005. The Soy Isoflavone Daidzein Improves the Capacity of Tamoxifen to Prevent
Mammary Tumors. Eur. J. Cancer Res., 41(4):647-54.
17. Lin, X., Yu, Y., Zhao, H., Zhang, Y., Manela, J. and Tonetti, D.A. 2006. Overexpression of
PKCα is Required to Impart the Estradiol Inhibition and Tamoxifen Resistance in a T47D
Human Breast Cancer Tumor Model. Carcinogenesis, 27(8):1538- 46.
18. Tonetti, D.A., Zhang, Y., Zhao, Lee, S.B. and Constantinou, A. I. 2007. The effect of the
phytoestrogens genistein, daidzein and equol on the growth of tamoxifen-resistant
T47D/PKCα, Nutrition and Cancer, 58 (2): 222-229.
19. Rizzo, P., Miao, H., D’Souza, G., Osipo, C., Yun, J., Zhao, H., Mascarenhas, J., Wyatt, D.,
Hao, L., Yao, K., Rajan, P., Hicks, C., Siziopikou, K., Selvaggi, S., Koerner, F., Bashir, A.,
Bhandari, D., Marchese, A., Lendahl, U., Qin, J.-Z., Tonetti, D.A., Albain, K., Nickoloff
,B.J. and Miele, L. 2008. Cross-Talk Between Notch and the estrogen receptor in breast
cancer suggests novel therapeutic approaches. Cancer Res. 68(13):5226-35.
20. Zhang, Y., Zhao, H., Asztalos, S., Chisamore, M.J., Sitabkhan, Y., Tonetti, D.A. 2009.
Estradiol-Induced Regression in T47D:A18/PKCα Tumors Requires the Extracellular Matrix
and the Estrogen Receptor. Molecular Cancer Res., 7:498-510.
21. Asztalos, S., Gann, PH, Dai, Y., Hayes, M., Nonn, L., Beam, CA, Wiley, EL, Tonetti, DA.
2010. Gene Expression Changes in the Human Breast Following Pregnancy. Cancer
Prevention Res.3(3):301-11.
22. Kim, HY, Sohn, J., Kastrati, I., Edirisinghe, P., Malloy, ME, Tonetti, DA, Thatcher,
GRJ. 2010. Click synthesis of estradiol-cyclodextrin conjugates as cell compartment
selective estrogens. Bioorganic Med Chem, 15;18(2):809-21.
23. Halasi, M, Zhao, H, Dahari, H, Bhat, UG, Gonzalez, EB, Lyubimov, AV, Tonetti, DA,
Gartel, AL. 2010. Thiazole antibiotics against breast cancer. Cell Cycle, 9:6, 1214-1217.
19
Tonetti, Debra A., Ph.D.
24. Tonetti, D.A., Gao, W, Escarzaga, D., Walters, K., Szafran, A.A. and Coon, J.S. 2012.
PKCα and ERβ are Associated with Triple-Negative Breast Cancers in African-American and
Caucasian Patients. International Journal of Breast Cancer, vol. 2012, Article ID 740353, 9
pages, 2012. doi:10.1155/2012/740353
25. Perez White, BE., Molloy, ME., Zhang, Y., Zhao, H., and Tonetti, DA. 2013. Extranuclear
ERα is Associated With Regression of PKCα-Overexpressing Tamoxifen- Resistant Breast
Cancer, Molecular Cancer 12(1):34.
26. Yun, J, Rizzo, P, Pannuti, A., Zhu, H., Hicks, C, Zhu, X., D’Souza, G., Backus, K.,
Denning, MF, Coon, J, Sun, M., Bresnick, EH, Osipo, C., Wu, J, Strack, P.R., Tonetti, DA
and Miele, L. 2013. PKCcauses estrogen-independent breast cancer cell growth via AP1/ Notch-4/cyclin D1 pathway. Oncogenesis, Aug 5;2:e60.
27. Zheng,Y., Wang, Z., Bie, W., Brauer, P., Perez White, B., Li, J., Nogueira, V.,
Raychaudhuri, P., Hay, N., Tonetti, D. Macias, V., Kajdacsy-Balla, A. and Angela
Tyner. 2013. Activation of Protein Tyrosine Kinase 6 at the Membrane Regulates the
Epithelial Mesenchymal Transition in Prostate Cancer. Cancer Research. 73(17):5426- 37.
28. Maoyu Peng, Rajyasree Emmadi, Zebin Wang, Elizabeth L. Wiley, Peter H. Gann,
Seema Khan, Nilanjana Banerji, William McDonald, Szilard Asztalos, Thao N.D. Pham,
Debra A. Tonetti, and Angela L. Tyner. 2014. PTK6/BRK is Expressed in the Normal
Mammary Gland and Activated at the Plasma Membrane in Breast Tumors. Oncotargets,
15;5(15):6038-48
29. Jamie C. Stanford, Christian Young, Donna Hicks, Philip Owens, Andrew Williams,
David B. Vaught, Meghan M. Morrison, Jiyeon Lim, Dana M. Brantley-Sieders, Justin
M. Balko, Debra Tonetti, H. Shelton Earp III, and Rebecca S. Cook. 2014 The prometastatic landscape of the breast during post-partum involution is triggered by MerTKmediated clearance of dying cells. J. Clin. Invest. 124(11):4737-52.
30. Molloy ME, Perez White BE, Gherezghiher T, Michalsen BT, Xiong R, Patel H, Zhao H,
Maximov PY, Jordan VC Obe, Thatcher GR, Tonetti DA 2014. Novel Selective Estrogen
Mimics for the Treatment of Tamoxifen-Resistant Breast. Mol Cancer Ther. 13(11):251526.
31. Weiss, MS., Peñalver Bernabé, B., Shin, S., Asztalos, S., Dubbery, S.J., Mui, M.D.,
Bellis, AD, Bluver, D., Tonetti, DA, Saez-Rodriguez, J, Broadbelt, LJ, Jeruss, JS. Shea,
LD. 2014. Dynamic transcription factor activity and networks during ErbB2 breast
oncogenesis and targeted therapy. Integrative Biology. Dec;6(12):1170-82.
32. Garth H Rauscher, Jacob K Kresovich, Matthew Poulin, Liying Yan, Virgilia Macias,
Abeer Mahmoud, Umaima Al-Alem, Andre A Balla, Elizabeth L Wiley, Debra Tonetti,
Melanie Ehrlich. 2015. Exploring DNA methylation changes in promoter, intragenic, and
20
Tonetti, Debra A., Ph.D.
intergenic regions as early and late events in breast cancer formation. BMC Cancer, Oct
29,15:816.
33. Asztalos, S., Pham, T., Gann, PH.., Hayes, M.K., Deaton, R., Wiley, E.L., Emmadi, R.,
Kajdacsi-Balla, Banerji, N., McDonald, W., Khan, S.A., Tonetti, D.A. 2015. High
incidence of triple negative breast cancers following pregnancy and an associated gene
expression signature. SpringerPlus Breast Cancer Collection Nov 19;4:710 .
34. Xiong, R., Patel, H., Gutgesell, L., Zhao, J., Delgado-Rivera, L., Pham, T., Zhao, H., Carlson,
K., Martin, T., Katzenellenbogen, J.A.,, Moore, T., Tonetti, D., Thatcher, G. 2015 Selective
Estrogen Mimic Partial Agonists (SEMPAs) for Tamoxifen-Resistant Breast Cancer. Journal
of Medicinal Chemistry, Dec 30.
35. Perez-White, B.E., Pham, T.N., Zhao, H. and Tonetti, D.A. Overexpression of PKCα in
T47D breast cancer cells induces migration via p120-catenin transcriptional downregulation.
In preparation for Oncogene.
INVITED REVIEWS
1. Tonetti, D. A. and V. C. Jordan. 1995. Possible mechanisms in the emergence of
tamoxifen resistant breast cancer. Anti-Cancer Drugs 6:498-507.
2. Tonetti, D.A. and V.C. Jordan. 1996. Targeted anti-estrogens to treat and prevent diseases
in women. Mol. Med. Today. 2:218-223.
3. Tonetti, D.A. and V.C. Jordan. 1996. Design of an ideal hormone replacement therapy for
women. Mol. Carcinogenesis. 17:108-111.
4. Jordan V.C., J.I. MacGregor and D.A. Tonetti. 1997. Tamoxifen: From breast cancer
therapy to the design of a postmenopausal prevention maintenance therapy. Osteoporosis
Int. Suppl. 1:S52-S57.
5. Tonetti, D.A. and V.C. Jordan. 1997. The role of estrogen receptor mutations in
tamoxifen-stimulated breast cancer. Invited review, J. Ster. Biochem. Mol. Biol. 62: 119128.
6. Tonetti, D.A. and Jordan, V.C. 1999. The ER as a target for the prevention of breast
cancer. Invited review, Journal of Mammary Gland Biology and Neoplasia, 4: 401-413.
7. Tonetti, D. A. Critical Commentary on “Phosphatidylinositol-3-OH kinase (PI3K)/AKT2,
activated in breast cancer, regulates and is induced by estrogen receptor (ER) via
interaction between ER and PI3K. Cancer Research, 2001, 61, 5985-5991.” Women
Oncol Rev, 2002; 2: 151-152.
21
Tonetti, Debra A., Ph.D.
8. Tonetti, D. A. Critical Commentary on “A naturally occurring MTA1 variant sequesters
oestrogen receptor-in the cytoplasm. Nature, 2002, 418:654-657. 2002.” Women Oncol
Rev 2002; 2: 407-408.
9. Tonetti, D.A. Commentary: Prevention of breast cancer by recapitulation of pregnancy
hormone levels. Breast Cancer Res 2004, 6:E8.
10. Pham, T.N. and Tonetti, D.A. The role of protein kinase C alpha (PKCα) in breast
cancer: A focus on endocrine resistant and triple negative subtype. 2015. Submitted to
Journal of Cancer Biology & Research
BOOK CHAPTERS
1. Benbrook, D. M., D. A. Tonetti and R. V. Miller. 1989. DNA gyrase of Pseudomonas
aeruginosa: Inhibition by quinolones. p. 171-186. In P. B. Fernandes, D. T. W. Chu, L.
Shen, P. Fernandes, L. O. White and G. K. Daikos (eds.), Quinolones, Proceedings of an
International Telesymposium, J. R. Prous Science Pub. Barcelona, Spain.
2. Huberman, E., D. A. Tonetti, M. Horio, S. Murao, and F. R. Collart. 1993. The control of
cell multiplication and differentiation in human myelomonocytic cells. In N. D'Alessandro,
E. Mihich, L. Rausa, H. Tapiero, and T. R. Tritton (eds.), Specific Approaches in Cancer
Therapy: Differentiation, Immunomodulation and Angiogenesis NATO ASI Series, 75:1732.
3. Collart, F.R., D.A. Tonetti, E. Huberman. 1996. The control of multiplication and
differentiation in human myelomonocytic leukemia cells. In A.S Tsiftsoglou, A.C.
Sartorelli, D.E. Houseman and T.M. Dexter (eds.) Tumor Biology: Regulation of Cell
Growth, Differentiation and Genetics in Cancer NATO ASI Series, H99: 113-128.
4. Tonetti, D.A. and V.C. Jordan. 1997. Targeted Antiestrogens. In Aldaz, M. (ed.),
Etiology of Breast and Gynecological Cancers, Wiley-Liss, Inc., New York, 245-255.
5. Jordan V.C., J.I. MacGregor and D.A. Tonetti. 1997. Can the new prevention strategies
reduce the incidence of ductal carcinoma in situ? In M.J. Silverstein (ed) Ductal
Carcinoma in Situ of the Breast, Williams & Wilkins, Baltimore, MD, 625-629.
6. MacGregor J., Tonetti, D.A. and Jordan V.C. 1997. The complexity of selective estrogen
receptor modulation: the design of a postmenopausal prevention maintenance therapy. In
R. Lindsay, D. Dempster and V.C. Jordan (eds) Estrogens and Antiestrogens, LippincottRaven Publishers, Philadelphia, PA, 261-277.
7. Gajdos, C., MacGregor, J.I., Tonetti, D.A. and Jordan, V.C. 2002. Can the New
Prevention Strategies Reduce the Incidence of Ductal Carcinoma In Situ? In M.J.
Silverstein (ed) Ductal Carcinoma in Situ of the Breast, Lippincott, Williams & Wilkins,
Philadelphia, PA, 497-501.
22
Tonetti, Debra A., Ph.D.
ABSTRACTS
1. Druse-Manteuffel, M., M. Collins, D. Tonetti, C. Waddell, and P. Patel. 1981.
Phenylketonuria (PKU), tetrahydroisoquinolines (TIQs) and neurological damage.
Neuroscience Abs.
2. Laten, H. M., S. Zahareas-Doktor, D. A. Tonetti, M. Quinn, R. M. Timmons, and C. Van
Kast.
1984. Synthesis and metabolism of isopentenyladenosine in yeast.
American Society for Microbiology.
3. Druse-Manteuffel, M. J., G. M. Kelly, D. A. Tonetti, and B. G. Oden. 1984. L-glutamate
binding to synaptic membranes: Influence of maternal ethanol consumption. Neurscience Abs.
4. Benbrook, D. M., D. A. Tonetti, and R. V. Miller. 1985. Inhibition of Pseudomonas
aeruginosa DNA gyrase by norfloxacin. Interscience Conference on Antimicrobial Agents and
Chemotherapy.
5. Tonetti, D. A. and R. V. Miller. 1988. Cloning and characterization of a DNA fragment
containing a gyrA analog from Pseudomonas aeruginosa PAO. American Society for
Microbiology.
6. Tonetti, D. A. and R. V. Miller. 1989. Analysis of the Pseudomonas aeruginosa qin gene: A
possible gyrA analog. Pseudomonas '89 Abs.
7. Tonetti, D. A., M. Horio and E. Huberman. 1992. Protein kinase C isotype expression in
PMA-sensitive and PMA-resistant HL-60 cell variants. American Association for Cancer
Research.
8. Tonetti, D. A., M. Horio, and E. Huberman. 1993. Protein kinase C plays an essential
role in human HL-60 leukemia cell differentiation induced by phorbol diesters. American
Association for Cancer Research.
9. Tonetti, D. A., C. Henning-Chubb, D. T. Yamanishi, and E. Huberman. 1994. Restoration of
susceptibility to differentiation induction by PMA in a PMA-resistant HL-60 cell variant by
transfection with PKC cDNA. J. Cell. Biochem. Suppl. 18D Wiley-Liss, Inc., New York.
10. Tonetti, D.A., Henning-Chubb, C. and Huberman, E. 1995. Electroporation lends clues to
the PMA-induced transduction pathway leading to human promyelocytic HL-60 leukemia
macrophage differentiation. American Association for Cancer Research.
11. Levenson, A.S., Tonetti, D.A., and Jordan, V.C. 1996. Paradoxical expression of transforming
growth factor (TGF) mRNA in MDA-MB-231 cells transfected with the estrogen receptor
(ER). American Association for Cancer Research.
12. Tellez, C., Tonetti, D.A., Tanjore, S., and Jordan, V.C. 1996. A study of the structure23
Tonetti, Debra A., Ph.D.
function relationship of pS2 and c-fos estrogen response elements (ERE) by modification of
the vitellogenin ERE. American Association for Cancer Research.
13. V. C. Jordan, Z. Chen, A.S. Levenson, J.I. MacGregor, H.D. Muenzner, S.B. Tanjore, D.A.
Tonetti and J.T. Yang. 1997. The regulation of transforming growth factor (TGF) .
14. Tonetti, D.A. and V.C. Jordan. 1997. PKC isozyme in hormone-independent breast
cancer. 20th Annual San Antonio Breast Cancer Symposium.
15. Tonetti, D.A., W. Grdina, H. Schurz, M. Chisamore, and V.C. Jordan. 1998. The role of
PKCoverexpression in hormone-nonresponsive breast cancer. 21st Annual San Antonio
Breast Cancer Symposium.
16. O’Regan, R., Tonetti, D.A. and Jordan, V.C. 1998. Comparison of tamoxifen and
raloxifene on the growth of endometrial cancer cell lines. 21st Annual San Antonio Breast
Cancer Symposium.
17. Chisamore,M.J., Lee, E.S., Jordan, V.C. and Tonetti, D.A. 2000. Novel antitumor effect of
estradiol in athymic mice injected with a T47D breast cancer cell line overexpressing
protein kinase c alpha. American Association for Cancer Research.
18. Fournier, D.B., Chisamore, M.J., Rademaker, A.W., Lurain, J.R., Jordan, V.C. and Tonetti,
D.A. 2000. Examination of protein kinase c expression as a possible prognostic factor in
endometrial carcinoma. American Association for Cancer Research.
19. Tonetti, D.A. M.J. Chisamore, Y. Ahmed and V.C. Jordan. 2001. PKC alpha is highly
expressed in T47D and MCF7 tumor models that regress upon estradiol administration.
American Association for Cancer Research.
20. Tonetti, D.A., Morrow, M., Kidwai, N, Gupta, A., and Badve, S. 2001. Elevated protein
kinase C alpha expression may be predictive of tamoxifen treatment failure. Accepted.
AACR-NCI-EORTC International Conference, Molecular Targets and Cancer Therapeutics.
Oct 29-Nov 2.
21. Manela, J., Chisamore, M.J., Jordan, V.C. and Tonetti, D.A. 2001. Is Overepression of
Protein Kinase C Alpha Required to Induce a Hormone-Independent Phenotype inT47D
Breast Cancer Cells. 24th Annual San Antonio Breast Cancer Symposium, Dec 10-13.
22. Tonetti, D.A., Pike, R., Pappas, S.G., Bentrem, D., Chen, B., Jordan, V.C. 2002. MDA- MB231 estrogen receptor beta stable clones exhibit distinct growth and transcriptional
characteristics. 25th Annual San Antonio Breast Cancer Symposium, Dec 10-14.
23. Pappas, S.G., Bentrem, D.J., Gajdos, C., Tonetti, D.A., Jordan, V.C. 2002. The shape of the
estrogen receptor (ER)-ligand complex predicts the agonist and antagonist actions of
endocrine disrupters in target tissues. 25th Annual San Antonio Breast Cancer
24
Tonetti, Debra A., Ph.D.
Symposium, Dec 10-14.
Constantinou, A.I., Tonetti, D.A., Callegari, E.A., White, B.E.P., Chelminska, A., Patel, H.,
and Lantvit, D. 2003. Soy protein isolate, but not genistein, enhances the
chemopreventive effects of tamoxifen against DMBA-induced mammary tumors in
female rats. American Association for Cancer Research, July 11-14, Washington D.C.
24. Tonetti, D.A., Lin, X., and Zhao, H. 2003. Signal transduction pathways involved in
estradiol-induced regression and tamoxifen-resistance in T47D:A18/PKCtumors. American
Association of for Cancer Research Advances in Breast Cancer Research, October 8-12,
Huntington Beach, CA.
25. Tonetti, D.A., Chisamore, M.J., Ahmed, Y., Zhao, H., Zhang, Y. and Sztark, A. 2003.
Mechanism of estradiol-induced regression of T47D:A18/PKCtumors involve the
estrogen receptor and interaction with the extracellular matrix. 26th Annual San Antonio
Breast Cancer Symposium, Dec. 3-6, San Antonio, TX.
26. Lin, X., Yu, Y., DeLeon, M., and Tonetti, D.A. 2004. Overexpression of PKC alpha is
required to impart the hormone-independent phenotype in T47D. Minisymposium, American
Association for Cancer Research, March 27-31, Orlando, FL.
27. Lin, X., Yu, Y., Zhao, H., Nasr, M. and Tonetti, D.A. 2005. Gene expression profiling in
estradiol-induced T47D/PKCα tumor regression. American Association for Cancer Research.
April 16-20, Anaheim, CA.
28. Zhang, Y., Zhao, H. and Tonetti, D.A. 2005. Raloxifene effectively inhibits the growth of
tamoxifen resistant T47D:A18/PKC tumors. 28th Annual San Antonio Breast Cancer
Symposium, Dec. 8-11, San Antonio, TX.
29. Tonetti, D.A., Beam, CA, Gao, W, Escarzaga, D., and Coon, J.S. 2006. PKCα expression in
African-American and Caucasian breast cancer patients. American Association for Cancer
Research. April 1-5, Washington, D.C.
30. Zhang, Y. and Tonetti, D.A. 2006. Changes in integrin expression are associated with
estradiol-induced T47D:A18/PKCα tumor regression. American Association for Cancer
Research. April 1-5, Washington, D.C.
31. Yun J, Denning, M., Tonetti DA, Miele L. Crosstalk between PKC and Notch-4 in
tamoxifen-resistant breast cancer. 29th Annual San Antonio Breast Cancer Symposium. Dec
14-17, 2006.
32. Rizzo, P., Yun, J., Hao, L., Tonetti, DA, Albain, K. and Miele, L. Cross talk between
Notch signaling and the estrogen receptor alpha in breast cancer suggests new therapeutic
strategies. 29th Annual San Antonio Breast Cancer Symposium. Platform presentation. Dec
14-17, 2006.
25
Tonetti, Debra A., Ph.D.
33. Zhang, Y., Zhao, Lee, S-B, Constantinou, A., Tonetti, D.A. The effect of isoflavones on the
growth of T47D/PKCtamoxifen-resistant breast cancer. American Association for Cancer
Research, Los Angeles, CA, April 14-18, 2007.
34. Zhang, Y., Zhao, H., Tonetti, D.A., Estradiol and bovine serum albumin conjugated
estradiol inhibit the growth of T47D/PKCα cells in 3-D cell culture. American
Association for Cancer Research, Los Angeles, CA, April 14-18, 2007.
35. White, B., Vraka, P., Tonetti, D.A., and Constantinou, A.I. Equol increases the in vitro
efficacy of tamoxifen. American Association for Cancer Research, Los Angeles, CA, April 1418, 2007.
36. Yun J, Denning MF, Bresnick E, Tonetti DA, Miele L Protein Kinase C alpha regulates
Notch-4 signaling via AP-1 in tamoxifen resistant breast cancer. American Association for
Cancer Research, Los Angeles, CA, April 14-18, 2007.
37. Zhang, Y., Asztalos, S., Zhao, H., and Tonetti, D.A. Gene expression regulated by
estradiol and fulvestrant in T47D/PKCα tumors. American Association for Cancer Research,
San Diego, CA, April 12-16, 2008.
38. Asztalos, S., Gann, P., Hayes, M., Nonn, L., Beam, C., Wiley, E. and Tonetti, D. Role of
lobular involution in pregnancy-associated breast cancer. CTRC-AACR San Antonio
Breast Cancer Symposium. Dec. 10-14, 2008.
39. White, B., Zhao, H. and Tonetti, D.A. Overexpression of PKCα in T47D:A18 cells results in
a noninvasive phenotype. American Association for Cancer Research, Denver, CO, April 1822, 2009.
40. Kundu, M., Zhang, Y., Zhao, H. and Tonetti, D.A. Estradiol induced regression of
T47D:A18/PKCα tumor involves translocation of estrogen receptor alpha from the nucleus to
the cytoplasm. CTCR-AACR San Antonio Breast Cancer Symposium. Dec 9-13, 2009.
41. Perez-White, B and Tonetti, D.A. T47D/PKCα cells are nonmigratory and noninvasive in
vitro despite tamoxifen resistance in vivo. CTCR-AACR San Antonio Breast Cancer
Symposium. Dec 9-13, 2009.
42. Asztalos, S., Gann, P.H., Hayes, M.K., Nonn, L., Wiley, E.L., Khan, S.A., Susnik, B.,
Diaz, L.K., Banerji, N., and Tonetti, D.A. Increased expression of inflammatory genes in
pregnancy- associated breast cancers.
CTCR-AACR San Antonio Breast Cancer
Symposium. Dec 9- 13, 2009.
43. Molloy, ME, Thatcher, GRJ, Bolton, JL and Tonetti, D.A. 2-(4-hydroxyphenyl)benzo[b]thiophen-6-ol, an estrogen-like compound, induces apoptosis in T47D/PKCα breast
cancer cells. CTCR-AACR San Antonio Breast Cancer Symposium. Dec 9-13, 2009. Han,
H. Frasor, J. and Tonetti, D.A. Overexpression of PKCα alters gene expression pattern in
T47D breast cancer cells associated with hormone-independent growth and tamoxifen
resistance. American Association for Cancer Research, Washington, D.C., April 17-21, 2010.
26
Tonetti, Debra A., Ph.D.
44. Tonetti, D.A., Asztalos, S., Gann, P., Hayes, M., Nonn, L., Wiley, E., Khan, SA, Susnik, B.,
Diaz L., Banerji, N. and Joshi, R. Gene Expression Patterns in Pregnancy-Associated Breast
Cancer. Gordon Research Conference, Mammary Gland Biology. Lucca (Barga) Italy, June
6-11, 2010.
45. White, BEP, Zhao. H. and Tonetti, DA. Overexpression of PKCα in T47D breast cancer
cells induces migration via p120-catenin transcriptional downregulation. American
Association for Cancer Research, Orlando, FL, April 2-6, 2011.
46. Molloy, ME and Tonetti, D.A. Potential role for Src kinase inhibitors in PKCαoverexpressing breast cancer. American Association for Cancer Research, Orlando, FL, April
2-6, 2011.
47. Asztalos, A., Gann, PH, Nonn, L, Balla, AK, Macias, V, Deaton, RJ, Wiley, E and Tonetti,
DA. The effects of pregnancy on ERα and Her2/neu protein expression in the normal breast.
American Association for Cancer Research, Orlando, FL, April 2-6, 2011.
48. Kundu M, Zhang Y, Zhao H and Tonetti DA. Extranuclear ERα plays an important role in
estradiol-induced regression of T47D:A18/PKCα tumors. American Association for Cancer
Research, Orlando, FL, April 2-6, 2011.
49. Rauscher GH, Ahsan H, Kibriya M, Dai Y, Wiley E, Kajdacsy-Balla A, Macias V, Levenson
V, Tonetti D, Ehrlich M. DNA methylation and hormone receptor status in breast cancer. 3rd
North American Congress of Epidemiology, Montreal, Quebec, Canada, June 23, 2011.
50. White, BE and Tonetti, DA. PKCα regulates FOXC2 expression in T47D breast cancer cells.
Advances in Breast Cancer Research: Genetics, Biology, and Clinical Applications, Oct 12,
2011.
51. Molloy, ME and Tonetti, DA. Overexpression of PKCα in T47D breast cancer cells alters
the CD44high/CD24low population. Advances in Breast Cancer Research: Genetics, Biology,
and Clinical Applications, Oct 12, 2011.
52. Perez White BE, Zhao, H., Kundu, M., Molloy, ME and Tonetti DA. Protein kinase C α
overexpression is associated with loss of membrane-associated E-cadherin and β-catenin in
T47D xenograft breast tumors. American Association for Cancer Research, Chicago, IL,
March 31-April 4, 2012.
53. Rauscher G and Tonetti, D. Potential role for hormonal and reproductive factors in explaining
ethnic/racial disparities in breast cancer aggressiveness. Society for Epidemiologic Research,
Minneapolis, MN, June 27-30, 2012.
54. Pham, Thao Nguyen, Asztalos, S., Weiss, M.S., Shea, L.D. and Tonetti, D.A. Overexpression
of protein kinase C alpha differentially activates transcription factors in T47D breast cancer
cells in presence of 17β-estradiol both in the 2D and 3D environments. CTCR-AACR San
Antonio Breast Cancer Symposium, Dec 4-8, 2012.
27
Tonetti, Debra A., Ph.D.
55. Espinoza, I, Pannuti, A. Caskey, M., Papa, F., Russell, R., Xhu, X., Hicks, C., Wang, G.
Tonetti, D. and Miele, L. Paralog-specific effects of Notch1 and Notch4 in endocrineresistant, ERα+ breast cancer cells: therapeutic implications. Submitted to The Notch
Meeting VII, Athens, Greece, October 2013.
56. Mary Ellen Molloy, Bethany Perez White, Huiping Zhao, Bradley T. Michalsen, Hitisha
K. Patel, Jiong Zhao, Rui Xiong, Marton I. Siklos, Gregory R.J. Thatcher, Debra A. Tonetti.
Selective estrogen mimics for the treatment of tamoxifen-resistant breast cancer. AACR San
Diego, CA April 7 2014.
57. Hitisha Patel, Rui Xiong, Jiong Zhao, Mary Ellen Molloy, Debra Tonetti, Gregory R.J
Thatcher. Lead based development and evaluation of selective estrogen mimics in tamoxifen
resistant breast cancer. AACR San Diego, CA April 7 2014.
58. Thao N.D. Pham, Szilard Asztalos, Peter H. Gann, Meghan K. Hayes, Ryan Deaton,
Elizabeth L. Wiley, Rajyasree Emmadi, Andre Kajdacsi-Balla, Nilanjana Banerji, Willam
McDonald, Seema A. Khan, Debra A. Tonetti. High Incidence Of Triple Negative Breast
Cancers Following Pregnancy And The Associated Gene Expression Signature. Illinois
Symposium on Reproductive Sciences, Chicago, Oct 13, 2014.
59. G. Thatcher, R. Xiong, H.K. Patel, J. Zhao, X. Liang, Y. Wang, M.E. Molloy, D. Tonetti
Potent, partial agonists at ERalpha as selective estrogen mimics for treatment of tamoxifenresistant breast cancer. EORTC-NCI-AACR, Barcelona, Spain, Nov. 18-21, 2014.
60. Gregory R. J. Thatcher, Rui Xiong, Hitisha K. Patel, Jiong Zhao, Xiao Liang, Yue-ting Wang,
Mary Ellen Molloy, and Debra Tonetti. Novel, non-uterotrophic, selective estrogen mimics
cause regression of tamoxifen-resistant breast cancer in 2D and 3D cultures and in mouse
xenograft models. CTCR-AACR San Antonio Breast Cancer Symposium, Dec 9-12, 2014.
61. Thao Pham, Bethany Perez-White and Debra A. Tonetti. Protein Kinase C alpha (PKCα) is
a novel regulator of FOXC2 and p120-catenin in triple negative and endocrine resistant breast
cancer. American Association for Cancer Research, Philadelphia, April 18, 2015.
62. Thao ND Pham, Bethany PE White, and Debra A Tonetti. PKCα mediates FOXC
transcriptional repression of p120-catenin in breast cancer. Submitted to American
Association for Cancer Research, New Orleans, April 2016.
63. Huiping Zhao, Thao Pham, Rajyasree Emmadi, Elizabeth Wiley, Michael Warso, Alejandra
Perez-Tamayo, George Salti, Kent Hoskins, and Debra A. Tonetti. Breast Cancer PatientDerived Xenografts: The University of Illinois at Chicago Cancer Center Experience.
Submitted to AACR: Patient-Derived Cancer Models: Present and Future Applications from
Basic Science to the Clinic, New Orleans, February 11-14 2016.
28